Ludger Ltd, Culham Science Centre, Abingdon, UK.
Division of BioAnalytical Chemistry, VU University Amsterdam, Amsterdam, The Netherlands.
J Crohns Colitis. 2023 Jun 16;17(6):919-932. doi: 10.1093/ecco-jcc/jjad012.
Biomarkers to guide clinical decision making at diagnosis of inflammatory bowel disease [IBD] are urgently needed. We investigated a composite serum N-glycomic biomarker to predict future disease course in a discovery cohort of 244 newly diagnosed IBD patients. In all, 47 individual glycan peaks were analysed using ultra-high performance liquid chromatography, identifying 105 glycoforms from which 24 derived glycan traits were calculated. Multivariable logistic regression was performed to determine associations of derived glycan traits with disease. Cox proportional hazard models were used to predict treatment escalation from first-line treatment to biologics or surgery (hazard ratio [HR] 25.9, p = 1.1 × 10-12; 95% confidence interval [CI], 8.52-78.78). Application to an independent replication cohort of 54 IBD patients yielded an HR of 5.1 [p = 1.1 × 10-5; 95% CI, 2.54-10.1]. These data demonstrate the prognostic capacity of serum N-glycan biomarkers and represent a step towards personalised medicine in IBD.
急需用于指导炎症性肠病（IBD）诊断时临床决策的生物标志物。我们在 244 名新诊断的 IBD 患者的发现队列中研究了一种复合血清 N-糖组学生物标志物，以预测未来的疾病进程。使用超高效液相色谱法分析了 47 个个体糖峰，从其中鉴定出 105 种糖型，并计算了 24 种衍生糖特征。进行多变量逻辑回归以确定衍生糖特征与疾病的关联。使用 Cox 比例风险模型预测从一线治疗到生物制剂或手术的治疗升级（风险比 [HR] 25.9，p = 1.1 × 10-12；95%置信区间 [CI]，8.52-78.78）。将其应用于 54 名 IBD 患者的独立复制队列中，得到 HR 为 5.1 [p = 1.1 × 10-5；95% CI，2.54-10.1]。这些数据表明血清 N-糖生物标志物具有预后能力，代表着 IBD 个性化医学的一个进步。
